Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$83.61 USD
+0.57 (0.69%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $83.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$83.61 USD
+0.57 (0.69%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $83.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
Stimulus or No? Plus News from GILD, Earnings from INTC & MAT
by Mark Vickery
Gilead (GILD) shares are up 4% in late trading on an announcement that the FDA has granted full approval to its remdesivir treatment.
Biotech Stock Roundup: BIIB Posts Q3 Results, VRTX Stops Study & Other Updates
by Zacks Equity Research
The biotech sector was in focus as Biogen's (BIIB) Q3 results disappoint, Vertex (VRTX) stops study and Regeneron's (REGN) Ebola drug gets FDA approval.
Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus
by Sweta Killa
The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.
Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Lilly (LLY) Witness Recovery in Sales in Q3 Earnings?
by Zacks Equity Research
Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) third-quarter sales.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $60.55, marking a -0.03% move from the previous day.
Gilead's (GILD) CAR T Cell Therapy Gets Positive CHMP Opinion
by Zacks Equity Research
Gilead (GILD) gets positive CHMP opinion for KTE-X19, a chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory mantle cell lymphoma.
Why You Should Invest in Genomics ETFs
by Neena Mishra
Genomics ETFs have surged of late; here's why
Regeneron's (REGN) Inmazeb Ebola Treatment Gets FDA Approval
by Zacks Equity Research
Regeneron (REGN) gets FDA nod for its triple antibody cocktail for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients.
Stocks Down 2nd Straight Day: Prime, Lilly, United Q3 & More
by Mark Vickery
Market indexes closed lower for their second-straight session, following a string of four days in a row higher.
Biotech Stock Roundup: REGN, GILD's Coronavirus News & Other Pipeline Updates
by Zacks Equity Research
Regeneron (REGN) and Gilead (GILD) continue to be in the spotlight on coronavirus-related updates.
Lilly's Coronavirus Antibody Study Paused on Safety Concerns
by Zacks Equity Research
Lilly (LLY) is developing antibody candidates for a potential COVID-19 treatment in several clinical studies.
Gilead Sciences (GILD) Stock Moves -0.09%: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $64.49 in the latest trading session, marking a -0.09% move from the prior day.
Gilead & Galapagos Announce Positive Data on UC Candidate
by Zacks Equity Research
Gilead (GILD) and partner Galapagos report positive data on filgotinib for the indication of active ulcerative colitis.
Lilly's Mirikizumab Retains Efficacy in Crohn's Disease Study
by Zacks Equity Research
Eli Lilly's (LLY) mirikizumab continues to show symptom improvement and reduction of intestinal mucosal inflammation in Crohn's disease patients after a year-long treatment in a mid-stage study.
AstraZeneca's Coronavirus Antibody Therapy to Enter Late Stage
by Zacks Equity Research
AstraZeneca (AZN) plans to start two phase III studies in October for evaluating its cocktail antibody therapy for COVID-19. To this end, the company gets $486 million funding from the U.S. government.
Gilead Up on Positive Final Results for Coronavirus Treatment
by Zacks Equity Research
Gilead (GILD) gains on results from the phase III ACTT-1 study of investigational antiviral Veklury for the treatment of adults hospitalized with mild-moderate or severe COVID-19.
Stock Market News for Oct 12, 2020
by Zacks Equity Research
Wall Street closed higher on Friday buoyed by market participants' expectations for a full-phased fresh fiscal stimulus before the upcoming U.S. presidential election.
Regeneron Gains on EUA Request for Coronavirus Treatment
by Zacks Equity Research
Regeneron's (REGN) stock up following the submission of a request to the FDA for granting an Emergency Use Authorization to its experimental COVID-19 treatment, REGN-COV2.
Lilly Seeks Emergency Use of Coronavirus Antibody Candidate
by Kinjel Shah
Lilly (LLY) applies to the FDA for Emergency Use Authorization of antibody therapy, LYCoV555. Releases promising data which shows that an antibody combination, LYCoV555 and LY-CoV016, is effective.
The Zacks Analyst Blog Highlights: Gilead, JNJ, Sanofi, BMY and MyoKardia
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead, JNJ, Sanofi, BMY and MyoKardia
Biotech Stock Roundup: ALXN to Raise Guidance, BMY to Buy MYOK & Other Updates
by Zacks Equity Research
The biotech sector remains in focus with regulatory, acquisition and other pipeline updates.
Current Outlook Gloomy
by Zacks Equity Research
Current Outlook Gloomy
A Murky Way Forward, Plus Lilly's New Candidate
by Mark Vickery
There is plenty to address in the coming weeks and months, though not much will be moving the needle this morning.
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $62.52, moving -1.7% from the previous trading session.